Life long Maverick: Seen it ALLl in 40 yrs of PROF. exposure as invest analyst/port mgr on the FRONT lines vs iHub Msg Bds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another Penny Stock BASKET CASE:
UNDisciplined & GREEDY never fails to be PULVERIZED:
Update:
Took a big position at 19 cts and traded out at 30 cts (even though it went to >50 cts) to avoid MAJOR debacle to 4 cts!
Never hurts to take a profit versus a complete wipeout.
XBI did BADLY!
Done with Msg Bds!
Doc_logic
Re:
Sadly, I said TIMBER:
50% decline in one month
There are so much better "Diamonds in the Rough" based on my being on The Front Lines"
despite whatever allure seen here
Whatever the promotions, let alone even MGT presentations, in the last 4 years NEW LOWS!
That is the nature of those here in LA, LA Land PERIOD! MASS Delusions.
It may? be bottoming but time tells all.
Too many other Diamonds in the Rough in this marketplace to even warrant attention to LGIQ
Re UMIBE's EXPOSE:Insights
IF one has NOT posted an intelligent & grateful response within 48 hours of UMIBE's post after the late Friday MASSACRE to 60 cts where ~8 Mln of it's 10 Mln daily traded... then it logically speaks VOLUMES about one's mindset atop their high horse.
IMHO what was evidenced in NWBO's late Friday MASSACRE was NOT CAPITUALIZATION nor that of a selling climax as it relates to Volume.
The entire sector was eviscerated having FAILED to exceed it's early Feb 2021 highs AND Failed it's significantly lower support level TWICE.
This amounted to a ~39% TUMBLE vs a ~76% SMASH for higher Beta NWBO.
The IWO ETF for comparison lost 17%!.
Unless NWBO get's a writeup or we get Big News,...... Since 2015,it has been FUTILE to make price (let alone Cloud NINE Potential Mkt capitalization) predictions. Without fail, those who did make those price predictions got a barriage of eggs on their face. Players and ConditionS CHANGE, most especially in Penny Stocks.PERIOD.
MOREOVER, maybe finally the reality has set in that there are DeepER Pocketed, Dark and Nefarious forces that I posted about since 2014 that very few knew about then!
Nevertheless:
THIS is still a PROCESS & The precursor of The Beginnings of a New Era for NWBO!
From more than TWICE near ASHES to The PHOENIX where The Legacies of Two Femme PHENOMS against Two Decades of INSURMOUNTABLES will be heralded for The Ages!
For the last 2+ years…Only allowed one NWBO post per day.
DIFFERENT STROKES FOR DIFFERENT FOLKS
UMIBE: Truly EXEMPLARY, as erudite as it get's without being an INSIDER and supercedes IMHO everything posted AND supports in greater detail, than I or the multitudes here could ever offer. Fortunately it is what I've espouseD and postED since 2015! Problem here for 99%: it has been beyond their closed mindset, AND Inexperience which the record here clearly has validated since 2015!
I take most all posters with a GRAIN of salt and have always marched to my own music versus the multitudes: As indicated I have consciously refrained from further contributions in last few years due to the rancor and vitriol ever present along with the grandstanding ring leaders who have been always BEHIND the eightball as it relates to the wrong roadmap from too many perspectives and clearly unproductive war of words typical of last four years.
A few weeks ago, in a Sunday hour, without interruptions, I devised ("For My Eyes Only")what I would do specifically in CEO Linda Powers shoes from a tactical and strategic perspective with her Game Plan on her FULL House of Cards and their highly critical, compacted and sequenced assemblage behind the heavy curtains including thoughts on an S1 and some voting directives for upcoming ASM: authorized shs, reverse stock split? ETC.
I have never waffled let alone had to revised my CEO nor Board member impressions.
That also applies to posters here! LotS of folks may have learned some very expensive investing 101 lessons.
ALL of us come with different viewpoints and perspectives based on our own set(S) of experience(S).
Too few posters are constructive or originators,let alone have the audacity of being bold, and being right for the right reasons.
Sadly, the preponderance has been clear, consistent errors of JUDGEMENT since 2015 compounded by the LOGICAL need for NWBO Corporate SILENCE(The Achilles Heels of investing in mine fields for Emerging BioTechs) after 2015's TWIN Hiroshima's: Neil Woodford's ONDRA Affair AND PHASE V ("Tome of Tombs"): pertinent here is: Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling
Especially the section: Mitts on 2010-2017 Big Short Targets: NWBO went from $1 Bln Mkt Cap to ~$20 Mln!
Fortunately I did not partake the technical advice proffered since late Nov courtesy of very high % of daily NWBO volume that was SHORT that was the harbinger of EROSION from $1.08 as well as too many leading, coincident and lagging technical indicators did NOT support the views posted.
Furthermore, I was early in indicating NWBO was at 52 week lows AND Tax Loss Selling Season was upon us! as the SNO event enthralled the multitudes.
AND I do not agree with the logic that late Friday detonation came from warrant holders.
Nevertheless:
THIS is still a PROCESS & The precursor of The Beginnings of a New Era for NWBO!
From more than TWICE near ASHES to The PHOENIX where The Legacies of Two Femme PHENOMS against Two Decades of INSURMOUNTABLES will be heralded for The Ages!
For the last 2+ years…Only allowed one NWBO post per day.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Missing in NWBO historical Recaps of Dan88 & Flipper: Thanks to both)
The NWBO history as portrayed yesterday by Flipper & Dan88 omitted their misleading & inaccurate scientific assist……. leading to NWBO purgatory since 2016:
Re Miltong’s cryptic strategic summary to which key posters would agree , although I am not surprised by the recent share plight by The Dark NEFARIOUS & very deep pocketed forces at play which I have amply profiled since 2014 which too few acknowledged until the precipitous off The Cliff’s Edge of the The Grand Canyon since 2015!
Since 2018, The Grand Strategist has “Behind the Curtain ……..many iron’s in the fire!”.
SP cracks in last two days were unnerving as too many were tapped out: not surprisingly along with evident lack of diversification in TAX LOSS season in the riskiest & most violative sector of all the market.
ADDED in last two days ( previous last purchase was $1.08) in the event of impending peer reviewed PUBLICATION that logically has MORE standing than any EVENT re Grandstanding posters re past SNO!
Useless IMHO to beat the drums daily on The OBVIOUS! Post SUBSTANCE vs Quantity! Or Grandstanding to sweet NOTHINGS.
What NWBO shares have done in last two weeks can be contrasted with just those two favorites of Thermos ……….that HAVE institutional holdings versus NONE for NWBO. YET BOTH “tanked”!).
Too FEW really do the COMPLETE Systems Approach Due Diligence on NWBO ( getting BETER due to post 2019 NEW & frequent posters with SUBSTANCE vs NOISE)…….let alone covering This Waterfront of Minefields!
AND the investment profile IMHO as portrayed by the body of posters says clearly to me since 2014 that NWBO is not a suitable investment vehicle as they have been demonstrably ILL equipped for the LONG Dark Journey: ANGST turned to VITRIOL! …. to glimmers of hope & realization damaged by sp declines in not just these three stocks but broad based in this sector!
Always easy to have an unending list of imponderables….. but undertaking that exhaustive methodical exercise at the very least relieves Stress and maybe gets one on the right path ( what both Femme PHENOMS have demonstrated to date).
Nevertheless:
THIS is still a PROCESS & The precursor of The Beginnings of a New Era for NWBO!
From more than TWICE near ASHES to The PHOENIX where The Legacies of Two Femme PHENOMS against Two Decades of INSURMOUNTABLES will be heralded for The Ages!
For the last 2+ years…Only allowed one NWBO post per day.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Thanks IkeEsq:
48 hourS of Cartharic CataclismS & RELIEF!
EARLY indications by Lykiri re NWBIO sponsored SNO event bags; CassieW’s viewpoint AND the Professional EXPERT Intelligence by MIDendream ‘s specific comments re FDA’s Coming Soon campaign rules strongly SUGGEST that the inscrutable, clandestine CEO Linda Powers has, not surprisingly, pulled yet “another rabbit out of the hat”: “ got FDA early blessings of SUCCESS”
The ESSENCE… “The Whole Loaf vs breadcrumbs” (coined years ago)
Re Flipper’s:
Maybe this is neither here nor there, (For a Change, I think you have logically and finally since 2015, hit the nail with your sledge hammer)but I think NWBO held the timing reigns prior to data lock. Occasionally during those years, LL expressed her anticipation of having the unblinded results out so that researchers could learn more about long term survivors. However, she referenced people to NWBO regarding when data lock might occur.]Last two sentences are exceptionally critical reminders in this EPIC Saga for the Ages)
After data lock, while NWBO is one of the parties that got to see the unblinded data, after it was unblinded and tabulated by statisticians, the primary person (besides the publisher) in control of publication timing is the principle investigator. So arguably, Dr. Liau is now the primary person relied upon to impress upon peer review, not only the quality of the paper, but its urgency. I think Dr. Liau is probably making certain, to the extent she can, that this publication sees the light of day sooner than later. (Given her 3 decade experience of deciding to go to medical school due to her mother dying of GBM and paying off her medical school loans WHILE being a Los Angeles real estate agent in the Summer only, to her ground breaking achievements in a male dominated neuro surgeon field to be heralded as the first woman to chair the American Board of Neurological Surgery and inducted to the National Academy of Medicine in 2018. Dr. Linda Liau not only broke many insurmountable barriers but enjoys widespread peer recognition along with hundreds of peer reviewed publications!)
I doubt there is anyone more appropriate to Shepard this study through the publication process, and I doubt anyone at NWBO would try to slow her down.(HUH? Not logical given the funding & especially the TENURE of her relationship with key NWBO mgt & KOL SAB : “I doubt anyone at NWBO would try to slow her down”
It is not possible to capture all the depth that composes Dr. Linda Liau: chair of the Neurosurgery Department at the University of California, Los Angeles; second woman to chair a neurosurgery program in the United States; first woman to chair the American Board of Neurological Surgery; first woman president of the Western Neurosurgical Society; and one of only a handful of neurosurgeons elected to the National Academy of Medicine. Her childhood and family history alone could fascinate several chapters of her life’s biography. Nonetheless, this brief biography hopes to capture the challenges, triumphs, cultural norms, and spirit that have shaped Dr. Liau’s experience as a successful leader, scientist, and neurosurgeon. This is a rare story. It describes the rise of not only an immigrant within neurosurgery—not unlike other giants in the field, Drs. Robert Spetzler, Jacques Marcos, Ossama Al-Mefty, and a handful of other contemporaries—but also another type of minority in neurosurgery: a woman.
Hutaaga Friday, 11/19/21 11:15:42 AM
Re: None 0
Post # of419297
Thought I would share this with you.
Talked to Dave and spent good 25 mins this morning.
The summary is, it is now really is depend on the journal publication.If they release something early, it may jeopardize the publication.
The holding is mostly due to these peer reviews were having hard times getting information because lots of the sources were shutdown due to covid.
Other than that, everything is lining up well.
So it is what it is.
He said they are working hard to stay on top of everything and trying to get it right, but can only do so much on their part.
He did mention that the average time from DL to publication is 13 months, so add a few months delays to that.
Fireman02360 Friday, 11/19/21 12:48:01 PM
Re: RedneckHoosier post# 419349 0
Post # of419425
I could care less about weak-handed common shareholders. Let them sell and move those shares into stronger hands. Most retail investors don't have the stomach (or understanding) for biotech investing, but for some reason, take positions in a sector in which they have no idea about, and expect timelines on their schedule. Its absurd. ALL biotechs are subject to delays, and most of these delays are out of the Companys hands....such as peer-reviewers not being available/delayed due to COVID, or inspectors being backed up with a heavy back-log in the UK. There is absolutely NOTHING Northwest can do but ride it out. Same with us, we ride it out. I dont care what anyone says, if the freaking trial failed, it would have been reported. PERIOD. Unless Powers would love to open up a huge amount of litigation and self-imposed criminal charges by an assortment of Regulatory Agency's who enforce fraudulent activity's by Companys' Management. While I think she has mis-managed parts of NWBO business, I do not think she is stupid, nor reckless in this regard. She knows better. Even if TLD doesn't happen until Q1/2 2022 WTF does it mattter??? The end-game is all the same. People need to straighten out their time-lines too match that of the Company. Only then will they find piece of mind in their investments
MI Dendream's expertise & others here…BUT RESULTS are what matters:
Re MI Dendream
FWIW to board members, since I know that I can be opinionated and extremely self-confident,(I AM ALSO,but I always look at ALL the MARKETPLACE facets and motivationS sizing them up (delineated in a 2018 post BUT clearly DISMISSED as irrelevant! ie Myopic CLOSED MindsetS) NEVER easy as the evidence here since 2015 has portrayed graphically)I had the opportunity to do a gut check tonight and did.
I ran my own little informal pole of seasoned industry professionals at a dinner this evening. I asked a group whether they could give me any rationale for releasing Phase 3 trial data in a publication without first presenting the data at a congress…not one idea came forward.
Then, I gave a brief history of the situation here and asked if it now makes sense to do so. I will share one quote that summarizes the unanimous consensus.
“If you want to fight off a short attack, you want to maximize exposure not minimize it. (THAT WAS MY CONCLUSION in 2015 that I also conveyed to both SVP Les Goldman and CEO Linda Powers AND WHY I HAVE NOT SEEN ANYTHING to this DATE TO DISLODGE: That too many have foolishly DENIED! for SIX depressing years amidst the Biggest BULL Market EVER.) In that situation, publishing without presenting makes no sense at all.”
It is not just me
Maverick_1 Friday, 10/19/1802:32:51 PM
Re: flipper44 post# 194015
Post # 194033 of 194034
FALLACY of Investors: SCIENTIFICALLY focused on the TREES (science)and clear disregard for the FOREST( Semi PRIVATE/Public co./COMPLETE Due Diligence/ Investment process/discipline etc): to NOT expect DILUTION from the end of 2015 says it ALL! especially with clinical halt
Everyone LOST PERSPECTIVE of the INVESTMENT PROCESS:
Emerging Biotechs have an INSATIABLE FUNDING NEED. Investors got bowled over with Neil Woodford's $190 mln in funding with an average per share cost near $7 (driving the stock to $12) AND MISSED his lack of credentials in that space. Sure he is Europe's Warren Buffet with his track record at INVESCO with industrials and some Big Pharma experience but Neil Woodford invested at the height of euphoria with emerging biotech space.
With Neil Woodford funding, CEO Linda Powers made a BOLD statement in her Sept 2015 Citytrust interview:" We are going it alone: Big Pharma has nothing to offer us but money": GO BIG OR GO HOME! With the Nov 2015 Ondra Affair when the stock was $4-$5 everyone should have SOLD! Guilty of lack of critical investment judgement let alone lack of investment DISCIPLINE owing to novice status: With the Governance suit/Cognate etc former financial partner Woodford and funds were clearly doing an underhanded raid on NWBO. So this board and ALL large holders still here as I've indicated got lost in the trees: Without $ funding and adept shorts and manipulators going full throttle OVERWHELM everyone in their own spoils and CEO Linda Powers has had to deal with a TITANIC.
So each of you could do all the subterfuging; camouflaging; obfuscation; spinning and cover ups and blame game thru your scientific tinkering on this board and Yahoo.
INVESTMENT EXPERIENCE in ALL the relevant areas with DEPTH pays unlike the 3-4 years of inner turmoil of lost of life savings; lost opportunity costs with the longest bull market in history that it has produced for many here. I haven't lost any money here, generated a 60% return from $6-$10 never had a restless night of sleep over NWBO where so many spend their 24/7/365 timeline.
CEO Linda Powers has to unshackle us (unblinding top line DC VAX L results along with partnering deal(S) are complex, time consuming affairs) from that albatross period from FALL 2015 for ALL from her inner circle to patients. Hopefully it will be her second and last attempt from the Ashes to the final Phoenix.
IMHO only.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Corrections to posters : Why NO PH3 Regulatory Affairs Officer & NO CFO : ALL previously posted by Moi BEFORE 2016!
Maverick0408 Tuesday, 11/16/21 10:06:42 AM
Re: pphmlover post# 417930 0
Post # of 418192
I don’t know why they don’t have a chief medical/regulatory officer on their team who has experience dealing with CROs and regulatory agencies. Unfortunately, the NWBO team have limited insight into who the right folks are and how to deal with them. Don’t understand their strategy. They continue to lose time and there is no end in sight! Unless Merck is working behind the scenes, which seems more and more unlikely given the slow progress.
The SAB and LL is not going to be able to provide meaningful input or for that matter have much experience/insight into this either. They have been in academia all their life!
profile pic HappyLibrarian
RE: Maverick0408 post# 417937
Post# of 418193 Go
Tuesday, 11/16/2021 10:10:08 AM
PlusOneCoin Icon
0
NWBO also does not have a CFO who is separate from CEO and probably for the same reasons - having a chief medical/regulatory officer would put someone on the team who might have opinions different than those of Linda Powers and whose expertise etc. could not be easily set aside or ignored.
Respond |
View Replies (1)
Bob_LobLaw
RE: Maverick0408 post# 417937
Post# of 418193 Go
Tuesday, 11/16/2021 10:16:32 AM
PlusOneCoin Icon
0
All by design. no CFO either to offer a checks and balance to how LP decides to finance the company. she can string this out as long as she wants with continued short term financing which dilutes us over and over
Respond |
View Replies (1)
Gus McCrae
RE: Maverick0408 post# 417937
Post# of 418193 Go
Tuesday, 11/16/2021 10:30:22 AM
PlusOneCoin Icon
0
Quote:
I don’t know why they don’t have a chief medical/regulatory officer on their team who has experience dealing with CROs and regulatory agencies. Unfortunately, the NWBO team have limited insight into who the right folks are and how to deal with them. Don’t understand their strategy.
Yep. It is a huge, huge deal that nobody working for the company has any experience with the BLA process. It is possible that the company has hired a consultant to act as the CRO, but if they have, they have not complied with their duties under the securities laws to tell us that.
From their current cash burn rate, it is obvious that they are not doing any substantial work to get a BLA ready for filing, nor are they doing anything substantial to address commercialization, which I guess makes sense since they must be at least 2 or 3 years away from commercialization. If they released TLD tomorrow, it would take them well over a year to get the BLA filed, and that is assuming they hired a consultant to help them with that process.
Respond |
View Replies (1)
biosectinvestor
RE: Maverick0408 post# 417937
Post# of 418193 Go
Tuesday, 11/16/2021 10:34:23 AM
PlusOneCoin Icon
0
I disagree. Linda is that person.[color=red][/color]
Respond |
No Replies Hopeforthefuture3
RE: Maverick0408 post# 417937
Post# of 418193 Go
Tuesday, 11/16/2021 11:07:50 AM
PlusOneCoin Icon
0
Maverick, in the past thermo has suggested that the nwbo management has a lack of experience and I tend to agree. Adding some knowledgeable experienced people in key areas imo would be a great plus.
At least from the Q appears have funds to continue for a few month. Nothing really new or any info on progress - imo
Near 52 week lows, see what SNO brings. Otherwise Bosch is to speak in January assuming they don't cancel
Stay tuned
Respond |
View Replies (2)
Poor Man -
RE: Maverick0408 post# 417937
Post# of 418193 Go
Tuesday, 11/16/2021 11:37:04 AM
PlusOneCoin Icon
0
Here is the one major positive about LP & LG: they’re relatively good at putting together deals. They acquired a controlling interest in NWBO for very little and made a nice deal to sell Sawston, as just two examples.
They’ve used that skill in negative ways as well, but I tend to believe they’re working with Merck - and probably the reason for the quiet period and all of a sudden being timely with their SEC reporting. No buyer wants to acquire another company’s contingencies and legacy issues, especially those that could emerge later.
Quote:
Unless Merck is working behind the scenes, which seems more and more unlikely given the slow progress.
Perceptive view by RedneckHoosier:
RedneckHoosier
RE: flipper44 post# 417220
Post#
417224
of 417283
Friday, 11/12/2021 07:37:15 PM
Yeah and that's great for anyone who's buying NWBO now as they're not competing with large institutional investors. So would you rather buy now on OTC? If you believe in NWBO then hell yes!
FALSE!: CEO Linda Powers did sell @17cts late 2018 : FOR TAX purposes!
Truly PATHETIC how so MANY here, since even 2014, could be so WRONG and so OFTEN on most EVERY critical ISSUE speaks VOLUMES! to Know It All???
Here are some of the highlights:
maverick_1 Friday, 06/14/19 02:59:26 PM
Re: maverick_1 post# 233200 0
Post # of 416289
IMHO NWBO CEO Linda Powers sold 4.4 mln shs at 17 cts: a small part of her NWBO shrs/options at yrend '18 at a SUBSTANTIAL LT Cap LOSS to clearly OFFSET her LARGE LT CapGAIN from the MLBO SALE of Cognate BioServices (CB):
NWBO Tax Side:
1)Safe to say that the NWBO shares used for the above were BOUGHT as high as $180: see this LT chart:http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=NWBO&insttype=&freq=2&show=&time=20
2) CEO Linda Powers sold 4.4 mln NWBO shrs @ 17 CENTS
Cognate BioServices (CB) Tax Side:
1) CB was a NEW Memphis, TN bought 2005? from bankruptcy court in the liquidation of Gene SYS?
2) In the last few years that facility was substantially expanded
3) I indicated within the last two weeks IMHO Cognate BioServices likely was sold in EXCESS of $75 mln
4) In the last 4 yrs "similar" plants were SOLD:
a)Caladrius Biosciences (CLBS)sold it's CA plant
Quote:
Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the Remaining 80.1% Interest in PCT for $75 Million
March 16, 2017
https://www.caladrius.com/press-release/hitachi-chemical-signs-agreement-to-purchase-from-caladrius-biosciences-the-remaining-80-1-interest-in-pct-for-75-million/
CLBS is but one of a handful of BOMBED OUT Buy recommendations by Steve G (Pyrrh + 5 other alias')
b) Novartis spent $43 mln in 2013! to acquire south NJ Dendreon plant when the later was under financial stress due to CLEAR INeptitude from MANY perspectives of CEO Mitch Gold:
Quote:
Dendreon today said it sold to Novartis its immunotherapy manufacturing facility in Morris Plains, NJ, for $43 million cash—the latest move by the troubled prostate cancer drug developer to right its own ship following more than a year of weaker-than-expected sales.
https://www.genengnews.com/topics/bioprocessing/troubled-dendreon-sells-off-nj-plant/
I will NOT spend more time on the above as I have already demonstrated in SPADES and across a wide spectrum the level of clear inexperience aside from EGO of NWBO owners or Naysayers.
That's why I always go the EXTRA MILE!
Just like what CEO Linda Powers has done in the last few years.
AND IMPORTANTLY others may react: Narcissistic through their OWN EGO or feel threatened.
ONCE AND FOR ALL:
Everything I have indicated is the furthest from that of being narcissistic or egotistic
Even without experience in a WIDE spectrum of high level encounters I have with an OPEN MIND: excelled.
That's why:
DIFFERENT STROKES FOR DIFFERENT FOLKS
flipper44
RE: maverick_1 post# 233327
Post# of 416290 Go
Friday, 06/14/2019 03:02:23 PM
PlusOneCoin Icon
0
You did go the extra mile on that. Thanks. Makes sense.
Respond |
No Replies
exwannabe
RE: maverick_1 post# 233327
Post# of 416290 Go
Friday, 06/14/2019 04:13:54 PM
PlusOneCoin Icon
0
Quote:
IMHO NWBO CEO Linda Powers sold 4.4 mln shs at 17 cts: a small part of her NWBO shrs/options at yrend '18 at a SUBSTANTIAL LT CapLOSS to clearly OFFSET her LARGE LT CapGAIN from the MLBO SALE of Cognate BioServices (CB):
NWBO Tax Side:
1)Safe to say that the NWBO shares used for the above were BOUGHT as high as $180: see this LT chart:bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=NWBO&insttype=&freq=2&show=&time=20
Nope.
The D-2 warrants in the transaction (which were exactly half of the restricted shares) only existed in conjunction with the recent preferred shares. And if the sale was those pref. and attached warrants, it likely was at $0 profit/loss.
True though that she certainly took a large cap gains hit on Cognate. Nice of NWBO to pay to build them up.
Respond |
View Replies (2)
profile pic maverick_1
RE: maverick_1 post# 233327
Post# of 416290 Go
Wednesday, 06/26/2019 04:54:21 PM
PlusOneCoin Icon
0
CEO Linda Powers HAS GNORMOUS unrealized NWBO LOSSES beyond one's comprehension! (really need a full time acclaimed Accounting FORENSIC to unearth going back to 2004!! TO PRESENT!!
Clearly exceeds by many orders of magnitude that of BasinStBlues investment consortium.
This can only change with top line approval!
Today is the first day I'm delving into the above! VERY TIME & LABOR INTENSIVE and the crew of distortnists can dredge up whatever: Par 4 the Course!
NONE OF THE ABOVE at this late stage is GOING TO SWAY my view!
SEE:http://securities.stanford.edu/filings-documents/1037/NWBO_01/200881_r01c_0701254.pdf
Don't forget there are two reverse stock splits:
1/15
1/16
Both were PRE 2013
DIFFERENT STROKES FOR DIFFERENT FOLKS
Respond |
View Replies (1)
=======================================================
maverick_1 Thursday, 07/07/16 10:56:34 PM
Re: iwasadiver post# 66343 0
Post # of 416286
Screening Halt (mid Aug 2015) caused the PRECIPITOUS (ie ~Zion's Natl Pks Angel Trail FALL):NWBO's descent to near death)obviously with theBIG assist from AFraudstein Manipulators along with the close to being in the casket effect from the Phase V report.
So with NO ONE of REPUTE to handle the uncertainty amongst institutional holders and more importantly, that of non diversified retail hands with deep pockets which only an institution can provide...... this clearly explains the horrific devastation to NWBO shrs. WHY do you think I've emphasized the need for a Baker Bros since Aug 2014.
HAD CEO Linda Powers done it's $130 mln of underwritings that has been handled by HC Wainwright (big fees but NO after market support!!) and INSTEAD decided to use Charden Capital with Dr. Gbola Amusa MD CFA on board since 2014,..... you would have NOT had this experience PERIOD! Proper placement of those $130 mln of NWBO shares ARE KEY!
Clearly NWBO Bd of Dir. Dr. Navid Malik had to be responsible for introducing NWBO to Woodford as well as in Tuesday's small direct private placement done by Charden Capital due in no small part to Navid's friendship with Dr. Gbola Amusa MD CFA
So without a strong foundation of US investor support mechanism in place, it has been EASY PICKINGS for AFraudstein's VAST Manipulator Network to DISTORT, FABRICATE: witness the aftermath of PhaseV report!! and the dissension it caused for Neil Woodford. It would not have happened to ie, Baker Bros
Great science.... but without the key necessary ingredients in place of both an experienced FDA Regulatory Affairs especially in PH 3 AND the clearly necessary after market support
As a public company, science can only take you so far, especially if one wants to go it alone.With very few exceptions, way too nerve wracking for an investor.
IMHO it did NOT have to happen this way!
My 2 cents.
Adam_Feuerstein
RE: maverick_1 post# 66345
Post# of 416286 Go
Friday, 07/08/2016 07:23:15 AM
PlusOneCoin Icon
0
Who is AFraudstein?
He sounds like a very powerful, influential guy.
Respond |
No Replies
doingmybest
RE: maverick_1 post# 66345
Post# of 416286 Go
Friday, 07/08/2016 10:05:05 AM
PlusOneCoin Icon
0
Maverick, I agree with your points. I have said that NWBO has tried to fight a war on two fronts, eluding both the grip of Wall St by trying to arrange its own financings rather than using typical financing arrangements with associated fees,... while also trying to avoid the grip of BP which could entail NWBO selling off a substantial piece of future potential revenue for a partnership early on. This is bold and a lot to try to do with each of these fronts requiring a lot of strategizing and execution. The Cognate relationship is part of their financing plan to avoid the need to finance an entire mfg network themselves. The halt was unfortunately a serious kink in the plans and I see them as fighting to hold on. I think they have the goods, just need to hold on a little longer.
Respond |
No Replies
Biosect post EXTRAORDIONAIRE! LP deliberates for the RIGHT TKO setup (said since 2015!+) vs the repetitious, destructive NOISE of grandstanding punditS that only help AF ; HF’s; Island boys; mkt mkrs; day traders, and induce MORE unneeded anxiety for holders!
biosectinvestor Member Level Tuesday, 11/09/21 10:14:52 AM
Re: scotty3371 post# 416045 of 416075
And yet the trial lasted well over a decade, almost 2 and has what appears to be a very substantial number of patients that should have died in 14 months or less, but did not… some lasting approximately the entire length of the trial and still well…
A trial that broke new ground in so many ways, that it has literally required complete rethinking of the relevant disease, it’s diagnosis and also broadly cancer and the body’s immune response.
A trial that likely helped open the eyes of regulators that the current regulators to the challenges for some diseases and cancers when you have a trial based placebo, and then to modify the requirements related to placebos.
A trial pushing the edges of new regulatory policies not even finalized yet…
It is all how you look at it and put it
Factoid: FEW have evaluated correctly the mindset of CEO Linda Powers. Paraphrasing what she stated: “NWBO was severely tested and we survived and are hardened for the challenges ahead”
Thanks MI Dendream for sharing your REALITY in the last few days, which based on my vast experience since 2014 with posters on both iHub and even Yahoo were NEVER equipped EVER to deal with Terre NOUVEAU!
The sole exception are those who only began accumulating when it CRATERED to below 35 CT’s and did NOT go overboard or VOCAL like some multi million share owners (ie lots of UK’ers )who were severely underwater and calling for the ouster of CEO Linda Powers (asinine mental depravity) in the 2018-2019 period.
Factoid: FEW have evaluated correctly the mindset of CEO Linda Powers with her FEROCITY and hammering ALL the nailS down since 2015!
Not only did she avoid bankruptcy a few times by refinancing TWICE :$10 mln Sawston UK Mortgage note due and subdivide Sawston, UK and then did the stupendous GEM deal with HuaWei that boatloads of UK’ers missed along with this entire board of posters being cajoled from 2015 till 2020 with disgraced and former largest owner Neil Woodford fund complex shut down/liquidated (peak was $18 billion under management).
So IMHO, one could still expect more AMAZEMENT from CEO Linda Powers based on her history of overcoming INSURMOUNTABLES! Years ago I cited here the template of high profile spotlighted Elon Musk who luckily raised $180 million in 12 hours back in 2011-2012. Elon has lost a lot of top echelon staffers: ie CEO of Lucid Air! and has been ridiculed to death and defied all the naysayers. I have had my own sets of experiences.
Her interests have been aligned with shareholders.
Venting maybe a needed relief valve, but relevant SOLUTIONS & RESULTS are all that one should focus on! which I am sure CEO Linda Powers adeptly weighs the Pros and Cons
From more than TWICE near ASHES to The PHOENIX vs time worn: “Petal to The Metal”
DIFFERENT STROKES for DIFFERENT FOLKS
UNTIL CEO Linda Powers begins unveiling her Tsunami of Killer Cards, daily volatility will prevail!
With the expiration on Nov 2 of Warrants Expiration which holders who post here never warned of the potential negative consequences…. left many in a quandary for the last three months with SEVERE UNDERPERFORMANCE re ANY related Index.
Furthermore over 2 years agos very FEW paid any attention to what CEO Linda Powers emphasized for 15 minutes at the annual Shareholders Meeting (see the transcript!)along with comments also by SVP Les Goldman
“Get YOUR NWBO shares Out of Street Name and in YOUR Name”.
IF that was complied with, CEO Linda Powers extensive analysis pointed to Naked shorts With massive Failed Delivers AND would have allowed those former 35 Cts warrants thereby avoided all those subsequent massive dilutions at LOW prices.
That is why she spent so much time at that Annual Shareholders Meeting on the subject!
Yet no one even after two weeks transpired even had ONE post about the above: except for MOI which got removed!
Instead HuNDREDS of posts solely dealt with TLD etc.
So instead of the the above happening, CEO Linda Powers had to come up with yet another of many Strategic Playbook’s since the 2015 Neil Woodford Ondra Affair.
Bottom line: SELF INFLICTED Stock Price Degradation with no sustaining price support by those peripheral penny stock recommendations to which CEO Linda Powers had to deal with working capital needs!
The Inexperience here displayed in SPADES for 5 years here since 2015 ignoring and misinterpreting key nuances in the complex nature of Biotech finances at the behest of the science which has also hit lots of ROCKS since 2015 has been displayed AMPLY.
After NWBO 3 month price decline and continual vaulted expectations get pushed out, sentiment wanes for newbies in the last year and subject to day trading.
IMHO Missing basic confirming technicals whether leading or coincident indicators.
Still: From TWICE near ASHES to THE PHOENIX and subsequent heralding the Legacy of two female phenoms!
DIFFERENT STROKES for DIFFERENT FOLKS
Todays news re UCLA’s Dr. Linda Liau joining CLPT Bd of Directors and Bigger Capital ALSO owns CLPT:
I turn over most every stone.
Even though I have been deluged in a good way to bypass reading most posts, I did NOTICE this post which really was INTRIGUING that expanded my Due Diligence by the other Maverick:
Maverick0408 Tuesday, 10/05/21 09:36:16 AM
Re: RedneckHoosier post# 406840 0
Post # of 414395
Bigger seems to a good guy who invests predominantly in biotech companies with bright future. I am extremely familiar with his other big investment over the last few years (CLPT)Worked very closely with majority of their leadership team including the CEO when we all worked for the same medical device company.
AMAZINGLY, DARK, LONG & WINDING TORTUROUS journey nearing a Foggy sunrise?
For many PRE 2018 NWBO investors it has been a nightmare.
Even for those in the last 52 weeks.....
compounded by Covid-19!
Revised FDA Immuno-Oncology Guidelines ETC
As most should have gleaned, NWBO from the outset was and is a semi private/public company under CEO Linda Powers since 2011. She has done an amazing job IMHO to date, with the exceptionS of having as her financial partners HC Wainwright and disgraced Neil Woodford especially, which has been her ALBATROSS since 2015 as profiled in many of my posts PRE 2018.
A special word of thanks to SecureInvest for his recent ascerbic, forthright multi-statements on ALL fronts confirming my own long held LONE Ranger professed & posted viewpoints which The Maddening, inexperienced crowd treated with clear disdain which is why it is like oil and water!
SecureInvest Friday, 10/29/21 01:36:02 PM
Re: Bright Boy post# 413682 0
Post # 413685 of 413794
I have full faith in management and the direction they are taking. I have found out from friends and colleagues that
LP is truly an amazing person
GBM'er: 53 yr old NYC raised & credentialed female Atlanta broadcaster for 23 yrs, Jovita Moore died 7 mos after surgery
Atlanta news anchor Jovita Moore dies months after brain cancer diagnosis
Atlanta news anchor Jovita Moore dies months after brain cancer diagnosis
https://www.cnn.com/2021/10/29/us/atlanta-news-anchor-jovita-moore-dies/index.html
Followup: Needed Retrospective..
Very FEW today (Exwan & his band + trolls excluded) would have expected NWBO be trading now at The 52 week LOW END of between 95 cts! and $2.12!).
Well, despite position building in my Other Biotechs (undiscovered,low market cap, patented, game changing with Experience by Thought leaders),my NWBO share position has expanded 65% in last 3 months.
And not surprisingly, the correlation of Daily % of NWBO volume SHORTED was spot on!
"From TWICE near ASHES to The PHOENIX!" coined when shares were below 25 cts.
DIFFERENT STROKES for DIFFERENT FOLKS
GBM 1.6X likelier in Males than Females and deadlier!
TPSO maybe a new biomarker for GBM: https://neurologyopen.bmj.com/content/2/2/e000069
“ Researchers analyzed the blood samples of 441 glioblastoma male and female patients to evaluate the correlation between the TSPO polymorphic variant rs6971, one of the most frequent polymorphisms (variants) found in humans, with the clinical outcomes of glioblastoma patients. Compared with female glioblastoma patients, males with the TSPO variant had shorter overall and progression-free survival times.”
https://www.news-medical.net/news/20211018/Study-reveals-a-link-between-neuroinflammation-protein-and-survival-outcomes-in-glioblastoma-patients.aspx
FWIW: MM’s on Level 2 were unsuccessful in putting a lid on BOTH:
1)Ask ( $ INTIMIDATION) &
2)Bid side: to make up their big size offering on Ask side.
As seen in the link below and my own monitoring (position building in OTHERS as I own a WAD of NWBO) the MM gang of Otcx, Gtsm, Csti, Cdel, and more recently Nite) got NWBO down to below $1.10 from $1.25 levels due to their collective MIGHT on receding light volume period until the selling dried up: DiWORSIFication woes ie CVM $25 to below $10, RTLF from 60 CT’s to new lows of 14-15 CT’s.
Only in last 7+ days on higher than significant avg daily volume have those MM’s have been unable to contain NWBO’s RISE…..despite daily SHORT volume spiking in the last month from 50% to 75%! as seen in this link:
https://shortvolume.com/?t=NWBO
DIFFERENT STROKES for DiFFERENT FOLKS
Jack2479 re “I see Sawston and ultimately Advent as being entirely funded by the shareholders of NWBO.”
On this MAJOR allegation Jack2479 and likely way too many here “shareholders” are missing the very BASICS of “Investing 101” which is WHY this board IMHO since 2014 may have business experience BUT are bereft!
REAL capital funding for ANY public company takes place ONLY when there is either:
1)A private placement or
2)an initial public offering AND as it relates to the above ERRONEOUS assertion above,
3)a secondary share offering whether through a private placement or through a follow on, AFTER being a public company.
The KEY is whether individual shareholders participated in a private or public offering by NWBO in FALL of 2014!! to amount to the purchase of the Sawston UK facility.
Clearly there was NO secondary offering to the public!
The funds for the Sawston, UK complex was through a private placement by Neil Woodford entities that was supposed to be NWBO’s long term financier: MISGUIDED!
ALL the above is IRREFUTABLE.
Par for the course here since 2014!
So ALL the emotions here, versus professional experience since 2014 are still on full display whether small or large shareholders (HUNDREDS of Thousand’s or even many MLNS of NWBO shares is also why NWBO shares are priced where they are at!
MANY here went down with Neil Woodford as he sunk 293,000 formerly well heeled UK investors. Also BreEXIT made it a compound fracture!
NWBO has way too MANY UK investors that have had to endure thru the chicanery since 2015.
That albatross CEO Linda Powers has carried has to be overcome that I avoided.
Today’S update re Neil Woodford:
https://www.thetimes.co.uk/article/how-woodford-investors-lost-1-1bn-from-bungled-fire-sale-f29cbljwl
No one else foresaw Neil Woodford as an UNFIT portfolio MISALLOCATOR that Fell on HIS OWN SWORD that I posted on ad nauseam that all here dismissed.
This is exactly why too many here should not invest in this space!
I always get the last laugh and why I rarely post in last few years.
DIFFERENT STROKES For DIFFERENT FOLKS.
IMHO, CVM Ph3 results affected NWBO shr's as CVM's shares were ON MARGIN and good many that Own BOTH got MARGIN CALLS.
Sensing the above, I added, for the first time in yearS, another 10OK shrs at this level to raise my cost basis from the 25 cts level.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Depositing NWBO shs at Fidelity Investments: Too MANY here have been guilty of short memories in this EPIC SAGA....especially in yet ANOTHER exotic area where with NO relevant experience, argumentative, ego driven “investors” have been wrong at every critical juncture from Fall 2015 thru 2020! That’s why in last few years, I and others rarely post!
Fidelity could be a potential HORNET’S NEST: SELF EXPLANATORY
maverick_1 Tuesday, 07/23/19 07:30:02 PM
Re: Dr Bala post# 237204 0
Post # of 376099
Those using Fidelity Investments: re CEO Linda Powers: "Get NWBO shs in YOUR NAME"
Quote:
Fidelity Investments is cutting out its middleman — Goldman Sachs — when dealing with Wall Street short sellers.
Quote:
The move comes as Fidelity and its rivals compete to cut fees on index funds, luring assets that can be used for more profitable businesses like securities lending, industry analysts say.
"The lower fees go, the more important securities lending revenue becomes," said Stephen Biggar, an Argus Research analyst who tracks financial services companies.
Securities finance is a big business, producing more than $9.9 billion of revenue globally for lenders last year, according to EquiLend, a securities-finance trading and clearing service owned by global financial firms
https://www.investmentnews.com/article/20190514/FREE/190519969/fidelity-drops-goldman-brings-securities-lending-in-house
Bloomberg
Markets
Fidelity Drops Goldman by Bringing Securities Lending In-House
Quote:
Securities lending plays an essential role on Wall Street. Fund managers, pension plans and insurers -- some of the largest players in the market -- make their stocks and bonds available to those who want to sell short, avoid a settlement failure or capture an arbitrage opportunity. Hedge funds are a major source of demand.
The borrowers put up cash collateral, which typically exceeds the value of the securities, that lenders reinvest for the life of the loan. The investment gains can go both to the fund that lends the securities, lifting its return, and to the management firm, boosting its revenue, according to a December report by Morningstar Inc
https://www.bloomberg.com/news/articles/2019-05-14/fidelity-drops-goldman-by-bringing-securities-lending-in-house
ALL of the above verifies what I have said MANY years ago: re meeting on the MetroNorth with the principal of one of the Wall Street's largest clearing firms then Pershing of Donaldson Lufkin Jenrette (a preeminent institution only firm started up by Yale MBA graduates): see Wiki:https://en.wikipedia.org/wiki/Donaldson,_Lufkin_%26_Jenrette
Note the alumni fo a Who's Who:
Notable alumni
Safra A. Catz — CEO of Oracle Corporation
David Einhorn - Founder and President of Greenlight Capital
Susan Decker — Former president of Yahoo! Inc
Jamie Dinan - Founder and Chairman of York Capital Management, LP
William H. Donaldson — Former chairman of the U.S. Securities and Exchange Commission (SEC)
Henry Jackson — Founder of OpCapita
Ken Moelis — Former UBS Investment Bank executive and founder of Moelis & Co.
Rich Riley, Senior Vice President & Managing Director of Yahoo! EMEA
Stephen A. Schwarzman—Chairman and CEO of the Blackstone Group
Daniel Scotto
Scott H. Aschoff - President & CEO of OCEANdrive Capital
Paul Singer - Founder and CEO of Elliott Management Corporation and The Paul E. Singer Foundation
Herald Ritch - Co-founder of Sagent Advisors
Gideon Yu — President & Co-Owner of the San Francisco 49ers and former CFO of Facebook and YouTube
Hamilton E. James — American billionaire businessman, and the executive vice chairman of The Blackstone Group
James "Jimmy" Neissa — CEO/Head of North America at Rothschild & Co and former joint global head of investment banking at UBS
Bruce Richards - CEO & Founder at Marathon Asset Management
IF you do NOT recognize the STATURE the above list of people have achieved then you are a NEOPHYTE Investor!
DIFFERENT STROKES FOR DIFFERENT FOLKS
Follow up re Retired EVP Merck's Roger Perlmutter
What the hell, since the time window is SHRINKING, I can now afford a possible blemish after 6 years of undeserved ridicule, disrespect by this vitriolic board.
The limitations here have been amply profiled and posted since 2015.
Thanks Bright Boy for sharing & confirming my own front line experience as both a stock analyst and money manager: even for those money managers who have posted here!
This has been an EPIC Saga as too few have BOTH the needed insight to decipher,
let alone the firsthand direct experience to deploy the right investment strategy AHEAD of the
Oncoming Curves witnessed.
DIFFERENT STROKES for DIFFERENT FOLKS.
Novocure's stock rockets into RECORD territory ~$200 after upbeat DMC review of lung cancer treatment trial
https://www.marketwatch.com/story/novocures-stock-rockets-into-record-territory-after-upbeat-dmc-review-of-lung-cancer-treatment-trial-2021-04-13?mod=mw_quote_news
Less than 2 years ago, some RAILED AGAINST NovoCure’s Optune (NVCR then in the high $40’s SIMPLY on the notion of just GBM (superficial & incomplete due diligence... been par for the course here pre 2020). So NVCR Fourfold in less than 2 years based on rising Institutional ownership.
https://investorshub.advfn.com/boards/replies.aspx?msg=150066019
Meanwhile I cited the background , success and EXPERIENCE of top performing T Rowe Prices Health Sciences money manager Ziad Bakri AND a Barons exclusive interview citing NovoCure as his best pick:
https://www.barrons.com/articles/how-to-invest-in-health-care-stocks-under-the-shadow-of-medicare-for-all-51563467481
And he worked at 2 of my alma mater’s Merrill Lynch & Cowen & Co.
One’s due diligence should be OPEN Minded & Open Ended!
However on way too many occasions from 2014 to 2019 it has sadly been way worse.....as previously posted.
Also stumbled upon this: https://investorshub.advfn.com/boards/replies.aspx?msg=148750673
Nevertheless this EPIC Struggle will hopefully be rewarding.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Hi 5’s to Jesster64 re his KISS (Keep It Simple Stupid)
Thank you jesster64 for underscoring The ESSENCE....... which is why many, like myself, have refrained from what you cite here as :
“ On Ihub they are overanalyzing every graph, every word, every detail. Bottom line is EVERYONE has to wait for the data. enough soapbox for one day ”
HOWEVER because NWBO has been a truly EPIC SAGA unlike any ever witnessed by any type of investor!
Individual investors hopefully fathom now what I’ve posted here since 2014!:
“Without the right set of institutional SUPPORT a stock goes nowhere”
When most every institutional investor sold out at $6 and all that was left was the
supposed “white knight: long term financial savior...... even CEO Lina Powers was spooked!
that necessitated the walking on land mines then eggshells witnessed from 2015 to 2020.
Sadly she chose the WRONG financial partner (I was the Lone dissenter:dozens of Maverick posts to unearth here)
ALSO IF an investor did their COMPLETE Due Diligence each one should have recognized in reviewing management and their backgrounds that NWBO has been a semi private company that is in the public domain that is run by CEO Linda Powers and her power: Board Members and limited staff under 15 undertaking MONUMENTAL challenges in besieged Emerging Biotech space littered with 90% corpses many doing reverse splits(NWBO had two prior to 2012)
So IF only the hundreds of online posters, even lurkers! on ANY social media platforms re NWBO did the following:
1)Have a DIVERSIFIED portfolio versus 90% here: Was their key retirement holding!
2)OBEY a cardinal rule of investing: MINIMIZE your losses AND PRESERVE your limited Capital!
3) A Margin Acct works as a TWO edge sword as too many found out belatedly: even as late as the
2019 NWBO Annual Shareholder’s Meeting when CEO Linda Powers stated her findings: “Many millions
Of illegal naked shorts ARE the result of NOT having YOUR NWBO shares in YOUR name. “ Many years before that I did post that the stock loan dept of financial firms are a large profit center! That was based on my meeting with a high level executive of Pershing & Co (formerly a division of DLJ) now a part of Bank of NY: https://www.pershing.com/
RATHER than:
1) Going with Bully Pulprits or The Crowd based on their limited and shallow experiences across MANY bandwidths requirED
2)Be Humble with an OPEN Mind!
3)RESPECT what the Market is CONVEYING!
4) NOBODY knows it ALL: I am STILL learning in this fast paced, dynamic world of change.
ALL should have EXITED with modest losses versus what has unfolded since 2015!
LOTS of folks having an ego and falling in love with their own perspective withOUT understanding the ENTIRE Capital Markets process AND it’s Player’s at various spectrums of the Capital. Market’s bandwidths: most never heard of, let alone deal with firsthand the dark, nefarious forces on Wall St or even read what I posted back in 2014! about DeepCapture.com re Dendreon.
AND what I’ve posted above is what I have seen as a Maverick since the 1970’s! working at the worldwide headquarters of Tier 1 NYC financial firms as a stock analyst and money manager having the rare, direct firsthand experience with the top shorting hedge funds.
IMHO ONLY since Sept 2020(Flashworks acquisition) has the OVERTIME Due Diligence here paid off.
AND in the last 6 months has the level of rancor, hostility and vitriol mostly dissipated!
ALL of that is the result of having a healthy influx of talented posting investors within the last 18 months to unearth and provide keen insights here.
Hopefully we are nearing the end of this 7 year long tunnel (EPIC SAGA) with TLD on DC VAX L.
ONLY with irrefutable high level trade publication of DCVAX L will there be a New Dawn and the potential of “sky’s the limit “.
One step at a time has always been my Mantra that few have espoused ...... consequences for exuberance’s especially here with long dry spells of SILENCE.. ie Pom Pom posters Merck buyout since 2019.
AND Reddit “investors”is NOT IMHO what CEO Linda Powers desires! and that NWBO is only marginally suitable for the typical Reddit investor!
DIFFERENT STROKES FOR DIFFERENT FOLKS
Depth of Gratitude Owed to DC VAX L perfector in this Complete expose on the life of UCLA’s Dr. Linda Liau:
Resiliency of a perpetual optimist: neurosurgeon Dr. Linda Liau
Jasmine A. Thum MD
View More
DOI link: https://doi.org/10.3171/2020.12.FOCUS20954
Online Publication Date: Mar 2021
It is not possible to capture all the depth that composes Dr. Linda Liau: chair of the Neurosurgery Department at the University of California, Los Angeles; second woman to chair a neurosurgery program in the United States; first woman to chair the American Board of Neurological Surgery; first woman president of the Western Neurosurgical Society; and one of only a handful of neurosurgeons elected to the National Academy of Medicine. Her childhood and family history alone could fascinate several chapters of her life’s biography. Nonetheless, this brief biography hopes to capture the challenges, triumphs, cultural norms, and spirit that have shaped Dr. Liau’s experience as a successful leader, scientist, and neurosurgeon. This is a rare story. It describes the rise of not only an immigrant within neurosurgery—not unlike other giants in the field, Drs. Robert Spetzler, Jacques Marcos, Ossama Al-Mefty, and a handful of other contemporaries—but also another type of minority in neurosurgery: a woman.
Keywords: women in neurosurgery; neurosurgical leaders; biography; immigrant neurosurgeons; diversity
ABBREVIATIONS ABNS = American Board of Neurological Surgery; GBM = glioblastoma; NAM = National Academy of Medicine; NIH = National Institutes of Health; PI = principal investigator; UCLA = University of California, Los Angeles.
Even among the highly select group of people that compose the neurosurgical community, Dr. Linda M. Liau stands out as an incredible anomaly. To those with limited insight into neurosurgery, she is a walking contradiction: small in stature and introverted by nature. But look closer and she is also a leader among leaders in the field, who paved a path for herself that few have before. Equal parts intelligent and humble, she found an identity within the profession that is uniquely her own.
Now the chair of the Department of Neurosurgery at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Dr. Liau is only the second woman, and the first Asian American woman, in the United States to chair an academic neurosurgical department (2017).1 To this day, in 2020, there have been only four female chairs of neurosurgery programs in the US. Dr. Liau has held many titles as the first woman: chair of the American Board of Neurological Surgery (ABNS) (2019–2020),2 president of the Western Neurosurgical Society (2015–2016), editor-in-chief of the Journal of Neuro-Oncology (2007–2017), elected member of The Society of Neurological Surgeons (2013)3 and the National Academy of Medicine (NAM) (2018),4,5 and countless other leadership and scientific accolades. She is a wild success by any standards.
Sitting across from Dr. Liau at a table, one sees her calmness and candor shining through, as well as her youthful glow; years of neurosurgery do not seem to have worn her down. There is a spark in her eye. She speaks in a reassuring, easy tone that one presumes her mother used even after a long day in the labor factories of downtown Los Angeles. This is Dr. Linda Liau’s story.
Part 1: Childhood
Dr. Liau’s mother, Sue Hong-Tsu Liau, came from a family of merchants. Sue’s mother (Linda’s grandmother) was born one of 9 girls into a wealthy Taiwanese family before the Chinese Communist revolution. Three of the girls were exchanged for an adopted brother, who acquired the family name and family inheritance. The women in the family inherited nothing; girls were viewed as a liability to be given as dowry to a future husband.
Customary for the time, at the age of 21 years, Linda’s mother was offered to was offered to her father, in an arranged marriage in the town of Tainan in southern Taiwan. Shortly after they were married, John emigrated to the US to attend graduate school at Case Western Reserve University. Sue, who spoke no English, traveled to the US to join John and, returning to Taiwan pregnant, gave birth to a daughter. Linda Liau was born in Tainan, Taiwan, in 1967 (Fig. 1).
FIG. 1.FIG. 1.
Family photograph of Dr. Linda Liau, younger than 1 year of age, in Tainan, Taiwan, 1967, with her mother, Sue Hong-Tsu Liau. Copyright Linda Liau. Published with permission.
Although her father studied in the US prior to her birth, Linda grew up in a decidedly traditional Taiwanese household, deeply entrenched with many gender disparities. She muses that her father likely had always wanted a boy, though he ended up with two girls, Linda and her younger sister, Anna, now a lawyer, who was born in Springfield, Ohio, following her mother’s return to the US. Linda recalls little of her childhood in Ohio except for the sideways glances or gawks she and her family received at the neighborhood Kmart. Revisiting childhood photographs, she reflects that she seemed to be the only non-Caucasian in her preschool classes.
When Linda was 5 years old, her parents moved their young family to Magnolia Avenue by the present-day University of Southern California. The area was decidedly inner-city and poor. Her family continued to be a recognizable minority among primarily Black and Hispanic neighbors. She attended the still-standing 32nd Street Elementary School, a public school with few resources at the time. In the third grade, her parents were able to secure her a spot at St. Vincent’s School (a predominantly Hispanic, Catholic school in downtown Los Angeles)—despite not being Catholic—with hopes for better educational resources.
Her parents valued education and did their best to provide for their daughters during their humble beginnings. Her father worked toward a real estate license, and her mother worked long hours at the equivalent of various sweat shops in downtown Los Angeles. Her mother held many odd jobs, one as a seamstress, which became Dr. Liau’s first job as a child. She earned a few cents per article of clothing by stringing up laces on women’s garments that her mother had brought home to work on.
Her mother in particular supported Linda’s academic success. Sue had only completed high school and had not been given a chance to pursue higher education. Before she married, Sue’s fate in life was to tend the modest family stall at the swap meet in their small hometown in Tainan, selling knick-knacks and wrinkled plums. Meanwhile, Sue’s family’s resources had been allocated to her three brothers: one became a doctor, one inherited the family stall at the swap meet, and one became a schoolteacher. Sue always envied her physician brother; it was her dream to pursue a career in medicine. Instead, her brother lived out her dream. He attended medical school, residency in New York, and moved back to Taiwan as a head and neck surgeon. Sue wanted more for her daughters than had been available to her.
A gifted child in math and science, Linda would soon be able to chart her own course in life, even without the resources that her parents could not offer her. By the fifth grade she had intellectually outgrown the material taught in class. She was unexpectedly pulled from classes for 3 days for a barrage of psychological and IQ tests by the school guidance counselor. Shortly thereafter, she was placed directly into seventh grade at a new college-prep school that was recruiting gifted students, Whitney High School, on which the book School of Dreams: Making the Grade at a Top American High School (2003) is based. By this time, her mother had started working as a bank teller and her father had earned his real estate license. Though still struggling to make ends meet, they were now better able to support her junior and high school education in another city, so the family moved to Cerritos, California.
Linda’s early academic prowess and internal drive were evident, thereafter earning her acceptance to a variety of nationally prestigious academic programs. But, despite all her accomplishments to date, Dr. Liau states that her mother remains the smartest person she has ever known.
Part 2: Education
Her mother’s words of constant encouragement, and her dream of being a physician to help people, lingered in Linda’s mind when she moved 3000 miles away at the age of 16 years to Brown University’s 7-year medical education program. During her undergraduate years, she majored in biochemistry and political science. Still in need of monetary support for her education, she arrived at Brown on work study. She found a job in a laboratory cleaning glassware. Her relentless curiosity and intellectual drive soon got the best of her, and she could not help but inquire about the work the postdoctorates were doing in the laboratory. Not long after, the laboratory principal investigator (PI), Dr. Jean M. Marshall, began involving the inquisitive young Linda in a variety of laboratory projects. The research focused on gastrointestinal motility, but Linda was singularly fascinated by the role of the nervous system in this complex process. Dr. Marshall began to invest in Linda’s education and helped her complete her honors thesis in preparation for medical school. Although she could have stayed at Brown, Linda was tired of the weather and desperately homesick to return to California. Her laser focus on research drew her to the heavy-hitting academic neuroscience research centers. She graduated from Brown in 1987 and then attended Stanford University School of Medicine (1987–1991).
Upon arrival at Stanford, the budding scientist contacted a variety of neuroscience professors and heard back from neurology professor Dr. Stephen J. Peroutka. Linda’s technical laboratory skills blossomed, and, despite her PI leaving academia for a job in industry partway through her training, she had enough data to publish her first paper on the characterization of a novel serotonin (5-HT1A) antagonist, which was a pindolol derivative affectionately called “Lindalol” in the laboratory. She lightheartedly says she should have been studying serotonin agonists; it would have made her a fortune in a time before Prozac, which is now widely used for depression. But like most things in her life, she takes this in stride. One gets the sense that, despite her proclivity for goal setting and achieving, maybe she is driven most by the thrill of the intellectual journey.
Perhaps the only major setback in life that she felt wholly ill-equipped to deal with was the passing of her mother in 1994 after a 15-year struggle with breast cancer. With her mother’s worsening health and her PI having left Stanford, instead of completing her PhD through the National Institutes of Health (NIH)–funded Medical Scientist Training Program for the development of physician-scientists, she was convinced by her mother’s looming mortality that she needed to “get on with life” and find a way back to Los Angeles to care for her. Linda returned to clinical rotations her 3rd year of medical school. Carrying her deeply rooted interest in neuroscience through her rotations, she could not identify with the hands-off feel of neurology, and felt a slow personal descent after rotating on a locked psychiatric ward with severely affected patients. She rotated on neurosurgery last and found a perfect fit, her sense of wonder again peaked.
On this rotation, Linda met Dr. Frances Conley, the first woman to be granted a tenured professorship in neurosurgery at a US medical school (1982), and first to be a full professor of neurosurgery (1986). Dr. Conley was both physically and intellectually impressive as an avid runner and javelin thrower, and a female general and spinal neurosurgeon who operated alongside all-male colleagues. She was also an early pioneer of the concept of harnessing the immune system, specifically by introducing bacteria (i.e., Corynebacterium parvum) into a tumor cavity to induce an immune reaction to potentially treat glioblastoma (GBM), which was thought of as a hopeless death sentence at the time. This was a radical idea for the time, potentially inspiring some of the groundwork for Linda’s later research on brain tumor vaccines and immunotherapy.
Dr. Conley, along with attendings such as Drs. Gary Steinberg, Larry Schuer, and John Adler (inventor of the CyberKnife), supported Dr. Liau as she pursued her passion for neurosurgery while a medical student at Stanford. She sought out UCLA as a perfect fit for residency; it not only brought her back “home” to Los Angeles to be near her ailing mother but also was famous for research in traumatic brain injury under the leadership of Dr. Donald Becker. She saw an opportunity to start research in the field of identifying biomarkers and new treatments for head trauma and brain injury.
In 1991, she graduated from Stanford Medical School (Fig. 2) and started neurosurgery residency at UCLA (Fig. 3). Though physically closer to her mother, Dr. Liau now lacked time to devote to Sue’s care. Her sister, Anna, took their mother to doctor appointment after doctor appointment. The family struggled to get Sue into a clinical trial for Herceptin, which was not yet FDA approved. By the time Sue’s care was transferred to UCLA oncologists Drs. John Glaspy and Dennis Slamon (who developed Herceptin), her cancer had widely metastasized, including to her brain. When Dr. Liau’s mother passed during her 4th year of residency, she experienced the greatest regret and guilt of her life: that she had been unable to spend more time caring for her mother in those final days.
FIG. 2.FIG. 2.
Dr. Linda Liau graduating from Stanford Medical School, 1991. Copyright Linda Liau. Published with permission.
FIG. 3.FIG. 3.
UCLA neurosurgery residents, 1997. Dr. Linda Liau is pictured in the front row, second from right. Copyright UCLA Department of Neurosurgery. Published with permission.
Ever trying to make sense of the insensible, Dr. Liau drastically shifted her intellectual and research efforts toward oncology. The year her mother died, she entered the fledging UCLA Specialty Training and Advanced Research (STAR) Program, allowing her to pursue a PhD degree during residency/fellowship, which she completed in 1999. That same year, she received an NIH K08 grant under the mentorship of Dr. James Economou (her mother’s surgical oncologist), applying the principles of immunotherapy for melanomas and carcinomas to cancers of the brain, specifically GBMs. He would go on to be her academic mentor throughout her professional career as a faculty member at UCLA. When Dr. Liau was elected to NAM in 2018, Dr. Economou was at the awards ceremony beaming with pride.
Around the time when Dr. Liau started on faculty at UCLA, her previous mentor, Dr. Fran Conley, still at Stanford, experienced a great setback. Dr. Conley was professionally respected among her male peers, who dominated the specialty at the time. But, having been passed over for chairman positions, she authored Walking Out on the Boys (1998), chronicling her challenges as a woman in medicine. She lost favor in the neurosurgical community thereafter. But she was 30 years ahead of mainstream culture, and though she was a martyr for the cause of advancing women in medicine, she is now noted as a pivotal catalyst in history books. The professional fall of a prodigious mentor greatly saddened Dr. Liau, but she intended that she too would be a role model someday, if only she made it that far.
Part 3: Professional and Adult Life
Dr. Liau is potentially one of the few neurosurgical figures who is simultaneously endowed with all aspects of success. In addition to being a coveted physician-scientist, she is a successful leader, role model, wife, and mother. She is commonly asked how she balances everything, to which she refreshingly and unabashedly responds, “You don’t. You can’t balance it all synchronously, but you can have it all, in parts, at various stages of your life.”
Stage 1: Mother, Scientist
She explains that early in her faculty career, she embarked on her greatest accomplishments to date with the births of her two children, Brandon Bergsneider, born in 1998 (she operated until her water broke in the operating room), and Bianca Bergsneider, born in 2001 (Fig. 4). Her pregnant belly seemed to limit new patient recruitment, so she made the most of her time as a young attending developing her laboratory and research, while being a mother to two young children alongside a husband who was also a busy practicing neurosurgeon. She somehow managed to breastfeed and pump between cases for a year for each of her children; it was not easy. But she smiles as she mentions their names.
FIG. 4.FIG. 4.
Family photograph (left to right): Dr. Marvin Bergsneider, Bianca Bergsneider, Dr. Linda Liau, and Brandon Bergsneider at the Rose Bowl, June 2019. Copyright Linda Liau. Published with permission.
With funding from her initial NIH K08 award, she hired Dr. Robert Prins, who had just completed his PhD at the Medical College of Virginia, as her first postdoc, and Sylvia Odesa as her laboratory manager. Dr. Liau seems to be deeply loyal; Dr. Prins now has his own laboratory and is a full professor in the Department of Neurosurgery at UCLA, and Ms. Odesa remains her laboratory manager to this day. In this early phase of her career, Dr. Liau made the seminal discovery that cytotoxic T cells can be activated in vivo to traffic into brain tumors, despite the long-held dogma at the time that the brain was “immune-privileged” and devoid of immune reactivity. 6 By the time she was a 5th-year faculty member, she had already completed the first-in-human treatment of a GBM patient with a dendritic cell (DC) vaccine (1999) and started the first-in-human phase I/II trials of an autologous tumor lysate-pulsed DC vaccine (2003).7 She had identified a novel glioma-associated growth factor gene8 and developed a new Listeria vaccine in animal tumor models.9 By the time she was 34 years old, she had earned three NIH R01 grants and an R21, a seemingly impossible academic feat in such a short period of time. As she would say, “the numbers speak for themselves,” and indeed others seemed to agree.
At one of her many national plenary talks about her research, she was approached by the American Association of Neurological Surgeons/Congress of Neurological Surgeons Tumor Joint Section president at that time, Dr. Joseph Piepmeier, and asked if she would be interested in joining the Tumor Section’s Executive Committee. Dr. Piepmeier became a mentor to Dr. Liau, and she later succeeded him as the editor-in-chief of the Journal of Neuro-Oncology. As she continued to develop her research acumen, she discovered a relationship between cytomegalovirus viral immunity and tumor immunity in GBM patients10 and was involved in the landmark discovery that cancer-associated IDH1mutations produce 2-hydroxyglutarate.11 Because of her groundbreaking research, her notoriety on the national stage grew and leadership opportunities started flooding in, whether for department chair, national board positions (Fig. 5), journal editorships, or standardizing policies regarding neurosurgical practice.
FIG. 5.FIG. 5.
ABNS 75th Anniversary and Mary Louise Spencer’s (executive administrator for the ABNS for almost 30 years; middle of first row, gray dress) retirement party, June 27, 2015. All of the other people in the photograph were current or former ABNS board directors. Dr. Linda Liau is pictured in the front row, third from right. Copyright American Board of Neurological Surgery. Published with permission.
Stage 2: Clinician, Leader
Having developed a strong basic/translational science foundation, Dr. Liau transitioned into the next stage of her career—a focus on patient care built upon a reverence for life, as she daily encountered GBM patients who had abandoned all hope. There are patients from her early immunotherapy vaccine trials who are now surpassing all odds, living up to 17 years after their deadly diagnosis was made, with phase III trials derived from her initial preclinical discoveries and phase I clinical results currently still ongoing. While she grew her clinical practice, her notoriety allowed her to grow an extended professional network within neurosurgery as well.
She speaks of her patients and neurosurgery colleagues fondly, as if they are extended family. In weaving together the narrative of her life, one starts to understand that she is the kind of person whose talent begets talent, whose relentless curiosity and perhaps joyful obsessiveness with her research engender infectious creativity and thoughtfulness in others.
Stage 3: Role Model, Historical Figure
Three years ago, Dr. Liau transitioned into her third professional stage of life as she took on the role of chair of the Department of Neurosurgery at UCLA (Fig. 6). She also transitioned into a symbol of inspiration nationally. She had accomplished firsts. She had become one for the history books. Her primary goals shifted from singularly personal research or clinical goals to facilitating the goals of others; shaping residents for their future, enabling other attendings to achieve their goals; and building the department she served.
FIG. 6.FIG. 6.
Dr. Linda Liau (foreground) as chair of the UCLA Department of Neurosurgery (resident and faculty members in the background) on Department Photo Day, July 2017. Copyright UCLA Department of Neurosurgery. Published with permission.
Deeply humble, she plays off her countless research, clinical, and leadership triumphs as mere kismet, but this volume of achievement cannot be accomplished without sheer grit and determination. Despite being a staunch intellectual, strongly swayed by numbers and statistics, it is clear that she is a deeply optimistic, hopeful individual. She has to be, in order to muster such resiliency for herself and for her patients. Her delightful wonder about the world is reflected in the glimmer in her eyes as she talks about all that she still hopes to accomplish in her already wildly successful career.
Part 4: Parting Wisdom
To merely chronicle the experiences of Dr. Liau’s life, the facts and the figures that make her curriculum vitae exceptional, is to overlook the extraordinary human being. Her humility, grace, and empathy, perhaps sometimes to a fault, often prevent those on the outside from truly understanding the daily challenges she must have faced. She was an immigrant and racial minority for most of her childhood, then rose as a star in a profession historically dominated by men.
Though she speaks little of it, one can infer the lifetime of explicit and implicit challenges she has faced, whether because of her race or her gender. Her extreme resilience, whether natural or developed as a coping mechanism to persevere, typifies who she is at her very core. Her sense of self is strong; it had to be to get this far in life and to live up to her strongest female role model, her mother. She is so deeply empathetic that she interprets slights and prejudices against her as a woman in the field as reflective of insecurities or ignorance of the offender. In such cases, Dr. Liau expands pattern recognition and demonstrates that women can excel in the profession. It is with singular insight that one can begin to see how—now in her seat of power, still likely subject to some nonbelievers—she is able to shrug off all that she has endured.
At the top of her field, Dr. Liau serves as a de facto mentor for young women in neurosurgery everywhere (Fig. 7). She always recommends that women medical students interested in neurosurgery talk to current residents; neurosurgery residency has significantly changed in the last 20 years, she says, perhaps with both a wistful and decidedly “as it should be” tone. I sometimes wonder how many volumes her challenging experiences could fill. I wonder how she endured both emotionally and intellectually. But I know she does not give it a second thought. She simply refuses to let the world dictate her life, perhaps as a reflection of her favorite quote:
No one can make you feel inferior without your consent.
— Eleanor Roosevelt
FIG. 7.FIG. 7.
Dr. Linda Liau and her first female trainees as department chair. A: Dr. Linda Liau (left) and Dr. Jos’lyn Woodard (right), fellow (2020 graduate). B: Dr. Jasmine Thum, post graduate year (PGY)–5. C: Dr. Sophie Peeters, PGY-4. D: Dr. Maya Harary, PGY-2. Copyright Sophie Peeters. Published with permission.
And so she doesn’t.
Acknowledgments
I would like to thank Dr. Linda Liau for generously sharing her experiences with me for this piece, and for graciously sharing her advice and wisdom with me throughout the years.
Disclosures
The author reports no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.”
The Whole Loaf vs some morsels.
DIFFERENT STROKES FOR DIFFERENT FOLKS
MASSIVE Irony that ever since 2014 Adam Fuerstein and the Wolfpack DENIGRATED NWBO while heralding Bluebird since 2014!
To wit:
https://medcitynews.com/2021/02/bluebird-scrambles-to-find-out-if-its-gene-therapy-caused-cancer-in-clinical-trial/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_medium=email&_hsmi=111551486&_hsenc=p2ANqtz-_zFtNzPu9Cfn3QdAs3bnW5ZitFpEJhHbGFE2uFJbqpyRDGEr6M2z_VYiu3MBhAB3j_ACzR6ultrsDZoJ08Ywo58WbHag&utm_content=111551486&utm_source=hs_email
Since 2014 Bluebird catapulted to $220/shr while NWBO CRATERED! from >$11 to 15 cents
In the last two years BLUE CRATERED from $220 to $30 while NWBO went from 15 cts to $1.55 now.
NWBO's Market Capitalization is now closer (WITHOUT Institutional Ownership!)to that of BLUE of $1.9 Bln.
Amazing to me that CYDY is similar to NWBO in that both have NO Institutional Ownership yet CYDY has a Market Capitalization of $3.3 Bln!
LOTS of Twist and Turns in this EPIC SAGA that few adroitly navigated in understanding ALL the forces at play in the investment process.
DIFFERENT STROKES For DIFFERENT FOLKS
Dr. Keyoumars Ashkan has been IMHO more vocal than others and likely one of the earliest proponents in unveiling DC VAX L TLD:
To wit ASCO 2018 (Dr. Keyoumars Ashkan comments back in May 2018 below in his plaudits on DC VAX L:
Dr. Keyoumars Ashkan:
“We also have to work with the regulatory bodies, and we probably ought to do that now, right, not even waiting, because we want this to be available to all the patients. Again, while it’s very nice about these studies… yes, those patients who are in better prognostic groups are going to benefit more… but there is a benefit to all patients. We want this available to absolutely everybody. And absolutely everybody cannot afford everything. So the cost needs to be brought right down,(NWBO Aug 2020 acquisition of FLASHWORKS, and again, I’m going to be fighting for that, because I want this available to all my patients. We need to get the prices down,(again:8/20 NWBO acquisition of FLASHWORKS) work with the regulatory bodies, approve it at a price which patients can afford. And I think that’s incredibly important. And you know what? I think you have to do ALL that… why? Because we owe it to these guys [points to the patients on the stage]. Thanks very much.”
“We also have to work with the regulatory bodies, and we probably ought to do that now, right, not even waiting, because we want this to be available to all the patients
Since last September it all reverts down to what I posted many years ago:
CEO Linda Powers has one shot to get ALL her cards lined up and which one to display and in what order
Retail "investor temperament runs The GAMUT!" unlike those ever having true firsthand institutional exposure.
Relevance of:
As the cognescenti has been acknowledging:
CEO Linda Powers and Dr. Linda Liau .....
nor would 68 other prominent neuro oncologists leave US in that Jeep's state of bewilderment/amusement?
AND BTW you should find RELEVANCE here:
https://www.thedrive.com/news/36651/theres-a-jeep-wrangler-dangling-off-a-cliff-in-california-after-some-fool-drove-up-a-bike-trail"
LOTS of GEMS for you to decipher and
hopefully assimilate and brainstorm for YOURSELF in the below article as to how this is related BOTH to the current stock market aberrations with many stocks AND especially as to how it relates to what has transpired in NWBO's Epic Saga:
Robinhood’s Collateral-Crunch Explanation Puzzles Wall Street
https://www.bloomberg.com/news/articles/2021-02-06/robinhood-s-collateral-crunch-explanation-puzzles-wall-street
AFTER reading the above article IF you cannot find the relationship to NWBO, either par for the course for the past(meaning in the last two years and especially since 2014) and why NWBO has been an EPIC Saga and STRUGGLE for 98% here, one should NOT be in this very high risk market segment of Emerging BioTechs: lots of folks here have evidenced this as NWBO went from $5+(late 2014) to peak of over $12((mid 2015) and never sold and buying all the way down BEFORE cratering @ 15 cents per share (thru mid 2019):
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=NWBO&insttype=Stock&freq=2&show=&time=20
Despite many posts over MANY years (ieS: "Goldman Sachs spending $100 Mln + on developing software to shave off milliseconds on trading"; "Get YOUR NWBO shares OUT of "Street Name!"; "Financial firms have a large profit center in Lending Out Shares!"; "Intercept's Nine Chapters in Illegal Naked Short Selling credited to TcTrader38"; SOS's Larry Smith recognizing Naked Short Selling very LATE; ETC ETC )on various key Capital Markets Process, too many here ignored or have assimilated let alone mastered... the nature of history repeating itself in many facets of life.
AND on the fundamentals just as BAD:
REDesign of DCVAX L Trial
No one in UK knew of how proliferate Mainland Chinese people were in Oxford, UK area where HuaWei bought Sawston complex from NWBO to help NWBO SURVIVE: rather that lotS posted: NEED NEW CEO! Shameful to put it mildly!
Even many high profile posters thought they knew or were prepared, but obviously the record here, in black and white demonstratively shows otherwise: FACTURAL
"C'est La Vie"
Successful Investing consistently is an Art Form if one is truly an investor AND lifelong student of the markets that does require an open mindset adjusting for the vagaries of the marketplace OR especially as it relates to NWBO in which deciphering the strategic mindset of CEO Linda Powers has been critical versus the never ending Piss and Moaning here of Whiner posters. Nothing constructive.... just Destructive.
NWBO is run by CEO Linda Powers and is not your garden variety Emerging BioTech as many have found out the hard way!
Fortunately, the nature of this board shows progress with NEW Blood.
Keeping your emotional side in a closet here is for your benefit and others.
DIFFERENT STROKES FOR DIFFERENT FOLKS.
Merck Taps Davis for CEO Role as Frazier Sets Plan to Retire ["https://www.bloomberg.com/news/articles/2021-02-04/merck-taps-davis-as-next-ceo-as-frazier-sets-plan-to-retire"]
DIFFERENT STROKES For DIFFERENT FOLKS
Thanks Biosect Re:
There are good regulatory reasons if you could not update something, and then suddenly you change behavior, it can be used against the company. Changes of behavior are a factor. They might not have updated before because they could not. It might even be something they would want to do, but the change in behavior from what was done before, nonetheless can be used as a weapon.
I don’t want to go into it. The worst thing is the constant querying and then one lays it all out and it’s a step-by step for how to mess up a company. I’ve been there before. It is the reason I went from posting links to legal resources and explanations in depth to being vague and dismissive. I learned my lessons. Shorts learn as you go along. They feed off of the conversations and turn ideas directly into tools to get what they want.
Further substantiation of NO Citadel ownership of Robinhood: I did state it's been backed by prominent VC's.
Robinhood Raises an Additional $2.4 Billion From Investors ["https://www.bloomberg.com/news/articles/2021-02-01/robinhood-raises-an-additional-2-4-billion-from-its-investors"]
Far from the Maddening Crowd.
Different Strokes for Different Folks.